Inovio Pharmaceuticals, Inc. (INO)
NASDAQ: INO · Real-Time Price · USD
1.700
+0.210 (14.09%)
At close: Aug 13, 2025, 4:00 PM
1.620
-0.080 (-4.71%)
Pre-market: Aug 14, 2025, 9:15 AM EDT
Inovio Pharmaceuticals Revenue
Inovio Pharmaceuticals had revenue of $182.34K in the twelve months ending June 30, 2025, down -69.19% year-over-year. In the year 2024, Inovio Pharmaceuticals had annual revenue of $217.76K, down -73.83%.
Revenue (ttm)
$182.34K
Revenue Growth
-69.19%
P/S Ratio
475.12
Revenue / Employee
$1,361
Employees
134
Market Cap
86.63M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 217.76K | -614.25K | -73.83% |
| Dec 31, 2023 | 832.01K | -9.43M | -91.89% |
| Dec 31, 2022 | 10.26M | 8.49M | 478.23% |
| Dec 31, 2021 | 1.77M | -5.64M | -76.05% |
| Dec 31, 2020 | 7.41M | 3.30M | 80.24% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
INO News
- 1 day ago - Inovio Pharmaceuticals, Inc. (INO) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights - PRNewsWire
- 3 days ago - Data Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP) - PRNewsWire
- 9 days ago - INOVIO to Report Second Quarter 2025 Financial Results on August 12, 2025 - PRNewsWire
- 5 weeks ago - INOVIO to Present at Upcoming Scientific Conference - PRNewsWire
- 6 weeks ago - INOVIO Announces Pricing of $25 Million Public Offering - PRNewsWire
- 6 weeks ago - INOVIO Announces Proposed Public Offering - PRNewsWire
- 6 weeks ago - Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development - GlobeNewsWire